Skip to content

Neonatal Antimicrobial Resistance and Outcome

Neonatal Antimicrobial Resistance and Outcome (neoAMRO)

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05743816
Acronym
neoAMRO
Enrollment
800
Registered
2023-02-24
Start date
2019-07-30
Completion date
2024-02-29
Last updated
2023-03-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neonatal Infection

Keywords

Infection

Brief summary

This is a multicentre observational study involving NNUs across the UK. Study personnel (Neonatologists and research Nurses) from these NNUs will identify eligible babies in whom a positive culture has been obtained. This study will help identify the infections leading to death in babies on UK neonatal units, define the clinical characteristics of babies dying from infections, and describe the management of babies dying from infections with a specific focus in their antimicrobial treatment.

Detailed description

The neonIN surveillance network captures data on episodes of invasive neonatal infection on a web-based database. Over 30 UK neonatal units currently contribute to this database in real-time. An episode of neonatal infection is defined as a positive culture collected from a normally sterile site such as the blood, cerebrospinal fluid (CSF) or urine (via catheter or suprapubic aspirate) for which clinicians prescribed at least five days of appropriate antibiotics. Clinical, demographic and microbiological data (including antimicrobial susceptibilities) are collected using a standardised online questionnaire. Denominator data regarding the total number of live-births and neonatal-admissions are collected for each neonatal unit. Through our study we aim to understand and describe better those infections and risk factors that lead to death. The case-control study will enable us to determine if gaps in optimal management, such as the wrong antibiotic or the wrong dose, are associated with poor outcomes. We can then translate such information into practice and develop / improve clinical guidance in order to improve outcomes. For the purpose of this study, we will request information on the baby's status (alive/died/not known) at 28 days after the positive culture was obtained. If the baby is alive, then this baby becomes eligible as a control. If the baby has died, then further details will be sought including the date of death and whether death was attributed to the infection.

Interventions

None listed

Sponsors

Antibiotic Research UK
CollaboratorUNKNOWN
St George's, University of London
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
28 Days to 12 Months

Inclusion criteria

• Infants on participating NNUs who have an episode of infection with a positive culture.

Design outcomes

Primary

MeasureTime frameDescription
Identifying infections5 yearsTo identify the infections leading to death in babies on UK neonatal units
Clinical characteristics5 yearsTo define the clinical characteristics of babies dying from infections
Management of infections5 yearsTo describe the management of babies dying from infections with a specific focus in their antimicrobial treatment and the antimicrobial resistance profiles of the relevant organisms

Secondary

MeasureTime frameDescription
Comparing bacterial infections5 yearsIn a case-control study we will assess the hypothesis that babies who die from bacterial infections on neonatal units do so because they receive inappropriate antibiotic management. To do this we will compare babies who die from bacterial infections with babies who survive bacterial infections on a range of factors including appropriateness, dose and timeliness of antibiotic use.

Countries

United Kingdom

Contacts

Primary ContactSana Ibrahim, BSc
sibrahim@sgul.ac.uk02087255382

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026